Abstract
In the face of the COVID-19 pandemic, understanding the interplay between environmental factors and virus spread is crucial for global preparedness strategies. This study explores how geographic latitude, sunshine duration, and vitamin D status were associated with the incidence and fatality rates of COVID-19 across 187 countries during the crucial early months of the outbreak. Data on the total number of COVID-19 cases by country were obtained from the United Nations database as of June 30, 2020. Univariate and multivariate regression analyses were conducted to determine the associations between COVID-19 cases and latitude, average hours of sunshine from January to June, and mean 25-hydroxyvitamin D (25(OH)D) levels. The average COVID-19 prevalence and mortality per million population were 2,087 and 69, respectively, with a case fatality rate of 3.19%. COVID-19 case fatality rate was positively associated with latitude (β = 0.030; 95% CI: 0.008, 0.052) and negatively associated with hours of sunshine (β = -1.51; 95% CI: -4.44, 1.41) and 25(OH)D levels (β = - 0.054; 95% CI: -0.089, -0.019) in adjusted regression analyses. Findings were similar for COVID-19 prevalence and mortality rate. These findings indicate that higher latitude and lower 25(OH)D levels was associated with increased COVID-19 severity and mortality.
While the data highlight potential links between vitamin D status and COVID-19 outcomes, causality cannot be inferred. Further research, including large-scale, well-controlled trials, is essential to determine whether vitamin D plays a definitive role in COVID-19 prevention and management.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
I declare that I have no financial interests that could have influenced the work reported in this paper.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study utilized publicly available, aggregated data at the country level from reputable sources such as the World Health Organization and the World Bank. No individual-level or personally identifiable information was collected or analyzed. Therefore, ethical approval and informed consent were not required.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
